News
-
GSK and Theravance have announced the launch of Anoro Ellipta umeclidinium/vilanterol inhalation powder in the United States, triggering a $30 million milestone payment from Theravance to GSK. The FDA approved Anoro Ellipta for the treatment… Read more . . .
-
Submit poster and paper abstracts by July 25, 2014 online at http://www.ddl-conference.org.uk/?q=abstractsubmissionDDL25. Visit http://www.ddl-conference.org.uk/index.php?q=abstractsubmission to view the session themes and download abstract guidelines. Read more . . .
-
The US FDA has proposed a new rule that would require e-cigarette makers to register with the agency, disclose ingredients used in their inhalation solutions, and provide scientific evidence to support claims of reduced risk… Read more . . .
-
Australia’s Therapeutic Goods Administration (TGA) has approved the Breo Ellipta fluticasone furoate/vilanterol for the treatment of asthma and COPD, according to GSK Australia and Theravance. GSK Medical Director Andrew Yeates commented, “We are delighted that… Read more . . .
-
The FDA has granted orphan drug designation to a ciprofloxacin DPI being developed by Bayer HealthCare for the treatment of non-cystic fibrosis bronchiectasis, the company has announced. The dry powder formulation, based on Novartis’s PulmoSphere… Read more . . .
-
Theravance has announced that its LABA Royalty Sub wholly owned subsidiary “issued $450 million in aggregate principal amount of PhaRMA 9% Notes due on or before May 15, 2029. The notes are secured by a… Read more . . .
-
GSK and Theravance have announced a Phase 3 study of fluticasone furoate (FF)/vilanterol (VI) (the Relvar Ellipta DPI) including Japanese COPD patients. In July 2013, GSK withdrew its application for Relvar for the treatment of… Read more . . .
-
Genoa Pharmaceuticals has announced that studies conducted in conjunction with McMaster University have shown that peak pirfenidone activity can be achieved by lung levels of the drug that remain for only a short period of… Read more . . .
-
Canada has approved GSK’s Incruse Ellipta umeclidinium (UMEC) DPI for the once-daily treatment of COPD, the first approval for its UMEC monotherapy, the company said. GSK received a positive opinion from the EMA’s Committee for… Read more . . .
-
US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland